1. 23andMe – U.S. FDA Enforcement Action (2013–2017)

Facts:

23andMe began marketing its “Personal Genome Service” directly to consumers, claiming it could provide health risk information for hundreds of diseases.

The company did not have FDA clearance for health-related interpretations.

Legal Issue:

Whether DTC genetic tests that provide medical risk interpretation require regulatory approval as medical devices.

Regulatory Action:

The U.S. Food and Drug Administration (FDA) ordered 23andMe in 2013 to stop marketing health-related interpretations until it obtained authorization.

Outcome:

• 23andMe paused health risk reports.
• In 2017, FDA granted authorization for limited health risk reports (e.g., BRCA mutation risk).

Legal Principle:

• Genetic interpretation services are treated as medical devices under U.S. law when they provide health risk analysis.
• Must comply with safety and efficacy standards before marketing.

Importance:

This is the foundational regulatory action defining DTC genetic tests as regulated medical products, not just informational services.

2. Illumina v. FDA Regulatory Dispute (Early 2010s – U.S.)

Facts:

Illumina, a major genomics company, challenged regulatory classification of certain genetic sequencing tools and tests, arguing that not all genetic testing components should be regulated as medical devices.

Legal Issue:

Whether genetic sequencing platforms used in DTC testing fall under FDA medical device regulation.

Outcome:

While not a single final court judgment, regulatory interpretation consistently favored FDA authority over clinical interpretation tools.

Legal Principle:

• Distinction between:
  • “Raw genetic sequencing tools” (less regulated)
  • “Clinical interpretation services” (heavily regulated)

Importance:

Helped define the regulatory boundary between lab tools and consumer-facing medical interpretation.

3. Myriad Genetics Patent Litigation (2013, U.S. Supreme Court)

Case: Association for Molecular Pathology v. Myriad Genetics

Facts:

Myriad Genetics held patents on BRCA1 and BRCA2 genes linked to breast and ovarian cancer. The company offered genetic testing and restricted others from testing those genes.

Legal Issue:

Can naturally occurring human genes be patented?

Judgment:

The Supreme Court ruled:

• Naturally occurring DNA sequences cannot be patented.
• However, synthetic DNA (cDNA) may be patentable.

Legal Principle:

• Human genes are part of nature and not patentable inventions.
• Restricting genetic testing through patents can limit access to DTC testing.

Importance:

This case opened the market for DTC genetic testing by removing monopolistic control over key genes.

4. Vitagene / Helix Regulatory Scrutiny (2010s–2020s, U.S. FTC Oversight)

Facts:

Companies like Helix and associated partners such as Vitagene offered DTC genetic-based wellness and diet recommendations.

The Federal Trade Commission (FTC) investigated claims about:

• Diet optimization based on DNA
• Lifestyle predictions
• Health improvement promises

Legal Issue:

Whether marketing genetic-based wellness claims without strong scientific backing constitutes deceptive advertising.

Outcome:

• FTC enforcement warnings and settlements in similar wellness-genetics cases.
• Requirement to clearly disclose scientific limitations.

Legal Principle:

• DTC genetic testing claims are subject to consumer protection laws against misleading advertising.
• Scientific validity must support marketing claims.

Importance:

Shifted focus from just medical regulation to consumer fraud protection in genetic testing markets.

5. UK Information Commissioner’s Office (ICO) Investigation into 23andMe (2017–2020)

Facts:

23andMe also operated in the UK and Europe, processing large volumes of sensitive genetic data.

Legal Issue:

Compliance with data protection laws under the EU framework (pre-GDPR and GDPR transition period):

• How genetic data is stored
• Whether user consent is fully informed
• Cross-border data transfer

Regulatory Action:

UK ICO reviewed compliance with data protection principles.

Legal Principle:

• Genetic data is classified as “special category personal data”.
• Requires:
  • Explicit consent
  • Strong security safeguards
  • Restrictions on third-party sharing

Importance:

Established that DTC genetic testing is not only a medical issue but also a data privacy and human rights issue.

6. DTC Ancestry Testing and Law Enforcement Access Cases (U.S., 2018–2023)

Example Context:

Companies like AncestryDNA and 23andMe store large genetic databases.

Key Legal Issue:

Whether police can access consumer DNA databases to solve crimes (e.g., Golden State Killer case).

Legal Development:

• Courts allowed law enforcement access via third-party genealogy databases in some cases.
• Some companies revised privacy policies to limit or disclose law enforcement sharing.

Legal Principle:

• Genetic data can be accessed under lawful investigative procedures, even if originally collected for consumer use.
• Raises Fourth Amendment (privacy search) debates in the U.S.

Importance:

Created ongoing legal tension between:

• Consumer privacy rights
• Criminal investigation interests

Key Legal Themes from All Cases

1. Medical Device Regulation

DTC genetic tests providing health information are regulated as medical devices (FDA approach).

2. Consumer Protection

False or exaggerated claims about genetic predictions can violate unfair trade practices laws.

3. Privacy and Data Protection

Genetic data is highly sensitive and treated as special category personal data.

4. Intellectual Property Limits

Genes cannot be monopolized through patents (Myriad case), enabling open competition.

5. Law Enforcement Access

Genetic databases may be used for criminal investigations under certain legal conditions.

Conclusion

Legal control of direct-to-consumer genetic testing is built through a combination of:

• Regulatory enforcement (FDA, FTC, EU/UK regulators)
• Constitutional and privacy law principles
• Patent law limitations
• Data protection frameworks

Unlike traditional medical testing, DTC genetic testing sits at the intersection of health law, consumer law, privacy law, and biotechnology regulation, making it one of the most legally complex areas in modern science policy.